Wasatch Photonics’ Optical Imaging Technology Creates Images of Coronary Artery Walls in Vivo

Patients undergoing angioplasty or other heart-related medical procedures could benefit from a new technology being developed with funding from the National Science Foundation (NSF). Optical imaging technology from Wasatch Photonics Inc. creates images of coronary artery walls in vivo to show where lesions and plaques have formed.

Physicians can use the images to determine the best course of action, including where a stent might be placed.

William J. Brown, vice president of business development at Wasatch Photonics, said the outcome of developing the technology will be the availability of a new tool to identify and treat coronary artery disease.

"This disease affects an estimated 16 million Americans and is a primary cause of heart attacks and strokes. Identifying and treating plaque buildup and other intravascular conditions could reduce the morbidity and mortality rates from coronary artery disease," he said. "Our technology, called intravascular optical coherence tomography, provides detailed imaging information for physicians to use in plaque assessment and stent implantation and monitoring. Our system, with its increased image resolution capability and competitive cost, will provide a significant improvement over the current systems."

Wasatch Photonics received a two-year Small Business Innovation Research (SBIR) Phase II grant for $498,325 from the NSF. The grant provides funding to continue developing the intravascular optical coherence tomography system. Brown said the grant also validates the company's approach.

"The National Science Foundation has a long history of funding both basic research and, via the SBIR program, commercialization of innovation at small companies," he said.

Wasatch Photonics Inc., with headquarters in Logan, Utah, and a division in the Research Triangle Park in Durham, N.C., opened an office in the Purdue Research Park of West Lafayette. Brown said opening the office offers strategic benefits to the company.

"We want to expand our presence in the Midwest, and opening the office in the Purdue Research Park is a natural fit for our goals," he said. "We also look forward to establishing a connection with Purdue University, one of the nation's pre-eminent research universities."

Officials from Wasatch Photonics will be at booth #1406 at the 245th American Chemical Society National Meeting & Exposition April 7-11 in New Orleans.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Wasatch Photonics, Inc.. (2019, February 27). Wasatch Photonics’ Optical Imaging Technology Creates Images of Coronary Artery Walls in Vivo. AZoOptics. Retrieved on April 25, 2024 from https://www.azooptics.com/News.aspx?newsID=17088.

  • MLA

    Wasatch Photonics, Inc.. "Wasatch Photonics’ Optical Imaging Technology Creates Images of Coronary Artery Walls in Vivo". AZoOptics. 25 April 2024. <https://www.azooptics.com/News.aspx?newsID=17088>.

  • Chicago

    Wasatch Photonics, Inc.. "Wasatch Photonics’ Optical Imaging Technology Creates Images of Coronary Artery Walls in Vivo". AZoOptics. https://www.azooptics.com/News.aspx?newsID=17088. (accessed April 25, 2024).

  • Harvard

    Wasatch Photonics, Inc.. 2019. Wasatch Photonics’ Optical Imaging Technology Creates Images of Coronary Artery Walls in Vivo. AZoOptics, viewed 25 April 2024, https://www.azooptics.com/News.aspx?newsID=17088.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.